24.04.2025, 09:54
Liksutov: Moscow SEZ residents have introduced 37 new medicines to the market in a year
Source: OREANDA-NEWS
OREANDA-NEWS In 2024, pharmaceutical enterprises-residents of the Technopolis Moscow special Economic zone (SEZ) - launched 37 new medicines on the market, Maxim Liksutov, Deputy Mayor of Moscow for Transport and Industry, said.
Among the drugs released are remedies for multiple sclerosis, cancer, chronic myeloid leukemia and other diseases.
"The capital plays a key role in the development of the domestic pharmaceutical industry and strengthening the country's drug sovereignty. On behalf of Moscow Mayor Sergei Sobyanin, the city has created a set of effective tools to support the industry, which allows it to regularly bring in-demand drugs to the market and increase production volumes. Today, eight resident enterprises produce vital medicines in the Technopolis Moscow special economic zone. During their activities, they have produced products worth over 74 billion rubles. In 2024, three companies from the capital's SEZ launched 37 new drugs for the treatment of socially significant diseases," Liksutov said, as quoted by the press service of the Moscow Department of Investment and Industrial Policy (DIPP).
The production of pharmaceutical companies is located at the Pechatniki and Alabushevo sites. They also participate in Russia's largest pharmaceutical cluster.
"Offset contracts are concluded with pharmaceutical companies from Moscow's SEZ, under the terms of which enterprises manufacture innovative medicines, and the city guarantees their purchase. The enterprises have high-tech production lines, modern laboratories, and invest in research and development activities. All this contributes to the creation of new effective medicines," said Anatoly Garbuzov, Minister of the Moscow Government and Head of the Moscow Diplomatic Mission.
In March 2023, the Ministry of Health of the Russian Federation registered the first Russian original drug for the treatment of multiple sclerosis. It was created by scientists from the biotech company BIOCAD and the Russian National Research Medical University named after N.I. Pirogov. The drug reduces the immune-inflammatory process in the central nervous system, which reduces the number of exacerbations in patients with multiple sclerosis.
The resident of the SEZ of Moscow invested more than 1 billion rubles in the research and creation of the drug. Production was successfully launched in 2024 at the Alabushevo site. Since then, the company has produced more than 7 thousand packages of medicine.
R-Oprah Company (R-Pharm Group of Companies) It is actively developing new types of medicines for the treatment of autoimmune, oncological, asthmatic, and other diseases.
"The project to create a modern pharmaceutical manufacturing complex on the site of the Moscow SEZ became possible thanks to an offset contract. In 2024, the resident launched a production site for the production of medicines in the form of soft gelatin capsules, which are used in the treatment of oncological diseases. Last year, the company also developed over 10 new medicinal products for the treatment of socially significant diseases," said Gennady Degtev, CEO of Technopolis Moscow SEZ.
In 2024, another resident company of the Moscow special economic zone, Amedart, began import-substituting production of 26 new drugs at the Pechatniki site. Among them are medicines for the treatment of oncology and HIV therapy. Launching the production of these critically important products is a significant step in providing Russian patients with affordable and high-quality medicines, the Diplomatic Mission noted.
New modern equipment allows the resident to produce up to 10 million packages of antiretroviral drugs for HIV therapy and up to 1 million packages of anticancer drugs every year. In total, the company's portfolio includes more than 100 items, they are included in the list of vital medicines. A total of 15 million packages of these drugs are produced per year.
The Technopolis Moscow Special Economic Zone is a territory with a special legal status, and it has a preferential business regime for investors. The area of the facilities of the territories on which the SEZ enterprises are located exceeds 390 hectares.
Among the drugs released are remedies for multiple sclerosis, cancer, chronic myeloid leukemia and other diseases.
"The capital plays a key role in the development of the domestic pharmaceutical industry and strengthening the country's drug sovereignty. On behalf of Moscow Mayor Sergei Sobyanin, the city has created a set of effective tools to support the industry, which allows it to regularly bring in-demand drugs to the market and increase production volumes. Today, eight resident enterprises produce vital medicines in the Technopolis Moscow special economic zone. During their activities, they have produced products worth over 74 billion rubles. In 2024, three companies from the capital's SEZ launched 37 new drugs for the treatment of socially significant diseases," Liksutov said, as quoted by the press service of the Moscow Department of Investment and Industrial Policy (DIPP).
The production of pharmaceutical companies is located at the Pechatniki and Alabushevo sites. They also participate in Russia's largest pharmaceutical cluster.
"Offset contracts are concluded with pharmaceutical companies from Moscow's SEZ, under the terms of which enterprises manufacture innovative medicines, and the city guarantees their purchase. The enterprises have high-tech production lines, modern laboratories, and invest in research and development activities. All this contributes to the creation of new effective medicines," said Anatoly Garbuzov, Minister of the Moscow Government and Head of the Moscow Diplomatic Mission.
In March 2023, the Ministry of Health of the Russian Federation registered the first Russian original drug for the treatment of multiple sclerosis. It was created by scientists from the biotech company BIOCAD and the Russian National Research Medical University named after N.I. Pirogov. The drug reduces the immune-inflammatory process in the central nervous system, which reduces the number of exacerbations in patients with multiple sclerosis.
The resident of the SEZ of Moscow invested more than 1 billion rubles in the research and creation of the drug. Production was successfully launched in 2024 at the Alabushevo site. Since then, the company has produced more than 7 thousand packages of medicine.
R-Oprah Company (R-Pharm Group of Companies) It is actively developing new types of medicines for the treatment of autoimmune, oncological, asthmatic, and other diseases.
"The project to create a modern pharmaceutical manufacturing complex on the site of the Moscow SEZ became possible thanks to an offset contract. In 2024, the resident launched a production site for the production of medicines in the form of soft gelatin capsules, which are used in the treatment of oncological diseases. Last year, the company also developed over 10 new medicinal products for the treatment of socially significant diseases," said Gennady Degtev, CEO of Technopolis Moscow SEZ.
In 2024, another resident company of the Moscow special economic zone, Amedart, began import-substituting production of 26 new drugs at the Pechatniki site. Among them are medicines for the treatment of oncology and HIV therapy. Launching the production of these critically important products is a significant step in providing Russian patients with affordable and high-quality medicines, the Diplomatic Mission noted.
New modern equipment allows the resident to produce up to 10 million packages of antiretroviral drugs for HIV therapy and up to 1 million packages of anticancer drugs every year. In total, the company's portfolio includes more than 100 items, they are included in the list of vital medicines. A total of 15 million packages of these drugs are produced per year.
The Technopolis Moscow Special Economic Zone is a territory with a special legal status, and it has a preferential business regime for investors. The area of the facilities of the territories on which the SEZ enterprises are located exceeds 390 hectares.
Комментарии